FDA approves Inovio's INO-3107 for recurrent respiratory papillomatosis
On October 30, 2026, the U.S. Food and Drug Administration approved Inovio Pharmaceuticals' INO-3107, branded Voceryq, for recurrent respiratory papillomatosis (RRP), a rare respiratory condition. The approval is Inovio's first approved product.
This is a valid forward-looking regulatory development: the FDA approved Inovio Pharmaceuticals' INO-3107 (Voceryq) for recurrent respiratory papillomatosis, creating potential commercial and cash-flow implications and marking Inovio's first approved product. The core approval and date are directly supported by the Reuters report and the contextual source; the exact approval time is not provided, so the timestamp uses the stated calendar date at 00:00 UTC as a date placeholder. The approval-related market-price move is intentionally excluded. INO is approved as the directly affected company, while PGEN is approved as a clearly exposed competitor with an existing therapy for the same indication. Other proposed stakeholders are excluded because their effects are indirect, speculative, or lack product-specific evidence.
The US Food and Drug Administration has approved Inovio Pharmaceuticals' NASDAQ:INO treatment for a rare respiratory condition, the regulator said on Friday, marking the company's first approved product.